NCT05107739View on ClinicalTrials.gov

A Study of DeTIL-0255 in Adults With Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

May 9, 2023

Study Completion Date

May 9, 2023

Conditions
Platinum-resistant Ovarian CancerEndometrial CancerCervical Cancer
Interventions
BIOLOGICAL

Drug Product De-TIL-0255

Autologous tumor-infiltrating lymphocytes

Trial Locations (4)

14203

Roswell Park Comprehensive Cancer Center, Buffalo

15212

Allegheny General Hospital, Pittsburgh

15213

UPMC, Pittsburgh

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
lead

Nurix Therapeutics, Inc.

INDUSTRY

NCT05107739 - A Study of DeTIL-0255 in Adults With Advanced Malignancies | Biotech Hunter | Biotech Hunter